



**Date: 14<sup>th</sup> November, 2018.**

To,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400 001.

Dear Sir/Madam,

**Ref : Script Id "BAJAJHCARE", Script Code "539872".**

**Sub: Outcome of Board Meeting held on 14<sup>th</sup> November, 2018 & Submission of financial result for half year ended 30<sup>th</sup> September, 2018.**

We hereby inform you that at the meeting of the Board of Directors of our Company held today i.e. 14<sup>th</sup> November, 2018 has inter alia considered and approved the following:

- Approved Unaudited Financial Result for the Half Year ended on 30<sup>th</sup> September, 2018 along with Limited Review Report.

A copy of the same is enclosed herewith.

We wish to inform you that Board Meeting commenced today at 4.00 pm and concluded at 5.35 p.m.

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully,

For and on behalf of Board of Directors  
of Bajaj Healthcare Limited

A handwritten signature in black ink, appearing to read 'Aakash Keshari', enclosed in a hand-drawn oval.

Mr. Aakash Keshari  
Compliance Officer

**BAJAJ HEALTHCARE LTD**

Registered Office : 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39/A, B-39 A/1, Road No. 23, Wagle Ind. Estate, Thane(West), Thane-400 604.

• Tel. : + 91 22 6617 7400 - 499 • Fax : + 91 22 66177458 • Website : www.bajajhealth.com

CIN No.: L99999MH1993PLC072892

# BAJAJ HEALTHCARE LIMITED

( CIN No. : L99999MH1993PLC072892 )

## STATEMENT OF ASSETS & LIABILITIES AS AT 30th September, 2018


(Rs In Lakhs)

Particulars		As at 30.09.2018 (Audited)	As at 31.03.2018 (Audited)	As at 30.09.2017 (Unaudited)
<b>A</b>	<b>EQUITY AND LIABILITIES</b>			
<b>1</b>	<b>Shareholders' funds</b>			
	a) Share Capital	689.96	689.96	689.96
	b) Reserves and Surplus	11,215.03	10,672.92	9,772.05
	c) Equity share warrants	-	-	-
	<b>Sub - Total - Shareholders' Funds</b>	<b>11,904.99</b>	<b>11,362.88</b>	<b>10,462.01</b>
<b>2</b>	<b>Non-current liabilities</b>			
	a) Long - term borrowings	1,750.30	2,147.51	2,426.07
	b) Deferred Tax Liabilities (net)	122.19	118.40	83.57
	c) Other long - term liabilities	-	-	-
	d) Long - term provisions	62.69	77.19	-
	<b>Sub - Total - Non-current Liabilities</b>	<b>1,935.18</b>	<b>2,343.10</b>	<b>2,509.64</b>
<b>3</b>	<b>Current liabilities</b>			
	a) Short - term borrowings	6,861.53	5,452.15	4,469.15
	b) Trade payables			
	(i) Total outstanding dues of micro enterprises and small enterprises	-	-	-
	(ii) Total outstanding dues of creditors other than micro enterpris and small enterprises	3,968.99	4,337.57	3,288.37
	c) Other current liabilities	2,472.33	2,592.71	2,076.88
	d) Short-term provisions	480.04	725.00	1,727.08
	<b>Sub - Total - Current Liabilities</b>	<b>13,782.88</b>	<b>13,107.43</b>	<b>11,561.48</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>27,623.05</b>	<b>26,813.41</b>	<b>24,533.13</b>
<b>B</b>	<b>ASSETS</b>			
<b>1</b>	<b>Non-Current Assets</b>			
	a) Fixed Assets	12,830.26	12,858.51	12,648.67
	b) Non-Current investments	0.31	0.31	0.31
	c) Deferred Tax assets (net)	-	-	-
	d) Long - term loans and advances	-	-	-
	<b>Sub - Total - Non-Current Assets</b>	<b>12,830.56</b>	<b>12,858.81</b>	<b>12,648.98</b>
<b>2</b>	<b>Current Assets</b>			
	a) Current investments	-	-	-
	b) Inventories	3,928.33	3,365.96	2,479.93
	c) Trade receivables	8,575.70	8,038.45	6,555.02
	d) Cash and cash equivalents	274.39	828.56	43.66
	e) Short-term loans and advances	-	-	-
	f) Other current assets	2,014.07	1,721.62	2,805.53
	<b>Sub - Total - Current Assets</b>	<b>14,792.49</b>	<b>13,954.59</b>	<b>11,884.15</b>
	<b>TOTAL ASSETS</b>	<b>27,623.05</b>	<b>26,813.41</b>	<b>24,533.13</b>

### Notes

- The above results were reviewed by the Audit Committee and approved by the Board of Directors of the Company in at their respective meeting held on 14th November 2018
- The Figures of the Previous year have been Re-grouped, Re-arranged, Re-Classified wherever considered necessary.

By Order of the Board  
For Bajaj Healthcare Limited

  
SKR Bajaj  
D.No.: 00225950  
Chairman and Managing Director

Date: 14th November 2018  
Place: Thane

**BAJAJ HEALTHCARE LIMITED**  
( CIN No. : L99999MH1993PLC072892 )  
**AUDITED FINANCIAL RESULTS FOR THE HALF YEAR 30th SEPTEMBER, 2018**


(Rs. In Lakhs)

Particulars	Six Months Ended			Year ended
	30.09.2018	31.03.2018	30.09.2017	31.03.2018
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
<b>I. Revenue from operations</b>	18,906.57	17,829.66	14,881.27	32,710.93
<b>II. Other Operating Income</b>	-	-	-	-
<b>III. Total Revenue (I+II)</b>	<b>18,906.57</b>	<b>17,829.66</b>	<b>14,881.27</b>	<b>32,710.93</b>
<b>IV. Expenses</b>				
(a) Cost of materials consumed (Including Other Direct Expenses)	15,694.60	13,544.11	12,090.28	25,634.39
(b) Changes in Inventories of Finished Good	-1,037.82	341.18	-356.15	-14.97
(c) Employee benefits expense	1,145.01	1,126.92	1,038.11	2,165.03
(d) Finance Costs	394.42	363.58	388.83	752.41
(d) Depreciation and amortisation expense	560.40	547.11	561.23	1,108.35
(e) Other expenses	1,192.56	557.30	446.62	1,003.92
<b>Total Expenses</b>	<b>17,949.17</b>	<b>16,480.20</b>	<b>14,168.92</b>	<b>30,649.12</b>
<b>V. Profit before exceptional and extraordinary items and tax (III-IV)</b>	<b>957.40</b>	<b>1,349.46</b>	<b>712.35</b>	<b>2,061.81</b>
<b>4. Other Income</b>	68.54	82.66	123.99	206.65
<b>5. Profit / (Loss) from ordinary activities before exceptional items(3+4)</b>	<b>1,025.94</b>	<b>1,432.12</b>	<b>836.35</b>	<b>2,268.46</b>
<b>VI. Exceptional items</b>				
<b>VII. Profit before Extraordinary Items tax (V+VI)</b>	<b>1,025.94</b>	<b>1,432.12</b>	<b>836.35</b>	<b>2,268.46</b>
<b>VIII. Extraordinary Items</b>				
<b>IX. Profit Before Tax (VII-VIII)</b>				
<b>X. Tax Expense</b>	400.65	475.45	274.38	749.84
<b>XI. Profit (Loss) for the period</b>	<b>625.29</b>	<b>956.66</b>	<b>561.97</b>	<b>1,518.63</b>
<b>XII. Profit / (Loss) from discontinuing Operations</b>	625.29	956.66	561.97	1,518.63
<b>XIII. Tax expenses of discontinuing operations</b>	-	-	-	-
<b>XIV. Profit / (Loss) from discontinuing operations (after tax) (XII-XIII)</b>	-	-	-	-
<b>XV. Profit (Loss) for the period (XI + XIV)</b>	<b>625.29</b>	<b>956.66</b>	<b>561.97</b>	<b>1,518.63</b>
<b>10. Extraordinary items ( net of tax expense)</b>	-	-	-	-
<b>11. Net Profit / (Loss) for the period (9+10)</b>	<b>625.29</b>	<b>956.66</b>	<b>561.97</b>	<b>1,518.63</b>
<b>12. Paid-up Equity Share Capital</b> (Face Value Rs. 10/-)	689.96	689.96	689.96	689.96
<b>13. Reserves excluding revaluation reserves as per Balance Sheet of Previous accounting Year</b>				7851.56
<b>XVI. EPS (Not Annualised)</b>				
(a) Basic	9.06	13.87	8.14	22.01
(b) Diluted	9.06	13.87	8.14	22.01

**Note :**

- The above results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on 14th November 2018.
- The figures for the half year ended 31st March, 2018 are the balancing figure between the audited figures in respect of full financial year and the published year-to-date figures upto the Half Year ended of the releveant financial year
- The figures for the previous period have been regrouped whenever necessary.
- The Statement as per Accounting Standard AS - 17 on segment reporting is given as Anneuxre A.

For Bajaj Healthcare Limited

  
 SKR Bajaj  
 D.No.: 00225950  
 Chairman and Managing Director

Date: 14th November 2018  
Place: Thane

**BAJAJ HEALTHCARE LIMITED**

( CIN No. : L99999MH1993PLC072892 )

**REPORT ON SEGMENT RESULTS FOR YEAR ENDED 30th SEPTEMBER, 2018**

Annexure : A

(Rs. In Lakhs)

Sr No	Particulars	Six Months Ended			Year ended
		30.09.2018	31.03.2018	30.09.2017	31.03.2018
		(Audited)	(Audited)	(Unaudited)	(Audited)
A	<b>Segment Revenue ( Excluding Intersegment Revenue)</b>				
	Bulk Drugs	18524.04	17427.26	14626.25	32053.51
	Formulations	382.53	402.40	255.02	657.42
	<b>Total</b>	<b>18906.57</b>	<b>17829.66</b>	<b>14,881.27</b>	<b>32,710.93</b>
	<b>Segment Revenue ( Intersegment Revenue)</b>				
	Bulk Drugs	378.63	305.17	447.32	752.49
	Formulations	51.88	48.57	32.14	80.71
	<b>Total</b>	<b>430.50</b>	<b>353.75</b>	<b>479.45</b>	<b>833.20</b>
	<b>Gross Segment Revenue ( Including Intersegment Revenue)</b>				
	Bulk Drugs	18902.67	17,732.43	15,073.57	32,806.00
	Formulations	434.41	450.97	287.16	738.13
	<b>Total</b>	<b>19,337.08</b>	<b>18,183.40</b>	<b>15,360.73</b>	<b>33,544.13</b>
B	<b>II. Segment Results</b>				
	<b>Profit / (Loss) Before Tax &amp; Finance Cost</b>				
	Bulk Drugs	2734.43	2361.03	1690.68	4,051.71
	Formulations	-121.50	-77.88	-133.93	-211.81
	<b>Total</b>	<b>2,612.93</b>	<b>2,283.15</b>	<b>1,556.75</b>	<b>3,839.90</b>
	<b>Less : Interest</b>	394.42	363.58	388.83	752.41
	<b>Other Unallocable Expenditure (Net)</b>	1192.56	486.96	332.07	819.03
<b>Net of Unallocable Income</b>	-	-	-	-	
<b>Total Profit Before Tax</b>	<b>1,025.94</b>	<b>1,432.61</b>	<b>835.85</b>	<b>2,268.46</b>	
C	<b>I. Segment Assets</b>				
	Bulk Drugs	26014.71	24,782.06	22,845.42	24,782.06
	Formulations	1608.04	2,031.04	1,687.41	2,031.04
	Others	0.31	0.31	0.31	0.31
	<b>Total</b>	<b>27,623.05</b>	<b>26,813.41</b>	<b>24,533.13</b>	<b>26,813.41</b>
	<b>II. Segment Liabilities</b>				
	Bulk Drugs	14769.99	15,017.98	13,793.74	15,017.98
	Formulations	283.16	314.15	193.82	314.15
	Others	664.91	119.98	83.57	119.98
	<b>Total</b>	<b>15,718.06</b>	<b>15,452.12</b>	<b>14,071.12</b>	<b>15,452.12</b>
	<b>III. Capital Employed</b>				
	<b>Total Capital Employed</b>	<b>11,904.99</b>	<b>11,361.29</b>	<b>10,462.01</b>	<b>11,361.29</b>
	<b>Total ( II+III)</b>	<b>27,623.05</b>	<b>26,813.41</b>	<b>24,533.13</b>	<b>26,813.41</b>

For BAJAJ HEALTHCARE LIMITED

Place : Thane  
Date: 14th November 2018



**S K R Bajaj**  
Director  
D.No.: 00225950


**PARESH  
RAKESH**  
  
**ASSOCIATES**  
Chartered Accountants

**Independent Auditors Review Report**

**To,**  
**The Board of Directors**  
**Bajaj Healthcare Limited.**

1. We have reviewed the accompanying statement of unaudited financial results of **Bajaj Healthcare Limited** for the half year ended 30<sup>th</sup> September 2018 being submitted by the Company pursuant to the requirement of regulation 33 of the SEBI ( Listing and Disclosure Requirements) Regulation, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with accounting standards and other recognized accounting practices and policies generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Paresh Rakesh & Associates**  
**Chartered Accountants**  
**FRN: 119728W**



**Rakesh Chaturvedi**  
**Partner**  
**Membership. no 102075**

**Date: 14<sup>th</sup> November 2018**  
**Place: Mumbai** *Anana*

